Clinical trial · Observational
SD vs. NSD Therapy in Elderly AML
Comparisiom of Standard (SD) Therapy and Non-standard (NSD) Therapy in Elderly Acute Myeloid Leukemia (AML)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is known that treatment outcome could be positively associated with treatment intensity. However, tolerance of chemotherapy decreases in the elder, some patients could not tolerate standard (SD) therapy and even died of side effect, and overall survival (OS) might not be prolonged. Whether all elder acute myeloid leukemia (AML) patients could benefit from SD therapy, or some should receive reduced-intensity therapy or even only supporting care remains controvertal. In this multi-center study, we are going to evaluate the benefit of SD and non-SD (NSD) therapy in elder AML patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-standard Therapy | — | UNRESOLVED | — |
| Standard Therapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- SD therapy
- description
- SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
- label
- NSD therapy
- description
- Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2 years
- description
- The time from AML diagnosis to patients death or last folloeing-up.
Secondary outcomes (3)
- measure
- Relapse-free survival
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Newly diagnosed AML exclusive of APL; Age from 60 years old to 75 years old. Exclusion Criteria: Any abnormality in a vital sign (e.g., organ function failure, serious infection ) Patients with any conditions not suitable for the trial (investigators' decision)
References
Publications (0)
Data not yet available